1. Publications ((*CORRESPONDING AUTHOR)
1. Lee S, Le Pichon CE, Adolfsson O, Gafner V, Pihlgren M, Lin H, Solanoy H, Brendza
R, Ngu H, Foreman O, Chan R, Ernst J, DiCara D, Hotzel I, Srinivasan K, Hansen D,
Atwal J, Lu Y, Bumbaca D, Pfeifer A, Watts RJ, Muhs A, Scearce-Levie K and
Ayalon G. (2016) Antibody-mediated targeting of tau in vivo does not require effector
function and microglial engagement. Cell Reports (in press).
2. Partridge M, Purushothama S and Lu Y* (2016) Emerging technologies and generic
assays for anti-drug antibody detection. Journal of Immunol Res (in press).
3. Lu Y*, Hoyte K, Montgomery WH, Luk W, He D, Meilandt WJ, Yu YJ, Atwal JK,
Scearce-Levie K, Watts, RJ, DeForge LE. (2016) Characterization of a sensitive
mouse Aβ40 pharmacodynamic biomarker assay for Alzheimer’s disease drug
development in wild-type mice. Bioanalysis 8(10):1067-75.
4. Kanodia JS, Gadkar K, Bumbaca D, Zhang Y, Tong RK, Luk W, Hoyte K, Lu Y,
Wildsmith KR, Couch J, Watts RJ, Dennis MS, Ernst JA, Scearce-Levie K, Atwal JK,
Prabhu S, Ramanujan S, Joseph S. (2016) Prospective design of anti-TfR bispecific
antibodies for optimal delivery into the human brain. CPT Pharmacometrics Syst
Pharmacol 5(5):283-91.
5. Zuchero YJ, Chen X, Bien-Ly N, Bumbaca D, Tong RK, Gao X, Zhang S, Hoyte K,
Luk W, Huntley MA, Phu L, Tan C, Kallop D, Weimer RM, Lu Y, Kirkpatrick DS,
Ernst JA, Chih B, Dennis MS, Watts RJ. (2016) Discovery of novel blood-brain
barrier targets to enhance brain uptake of therapeutic antibodies. Neuron 89(1):70-
82.
6. Bien-Ly N, Boswell CA, Jeet S, Beach TG, Hoyte K, Luk W, Shihadeh V, Ulufatu S,
Foreman O, Lu Y, DeVoss J, van der Brug M, Watts RJ. (2015) Lack of widespread
BBB disruption in Alzheimer's disease models: Focus on therapeutic antibodies.
Neuron 88(2):289-97.
7. Lu Y* and Meng YG. (2015) Quantitation of circulating neuropilin-1 in human,
monkey, mouse, and rat sera by ELISA. Methods Mol Biol 1332:39-48.
8. Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, Bien-Ly N, Hersom M,
Maloney JA, Meilandt WJ, Bumbaca D, Gadkar K, Hoyte K, Luk W, Lu Y, Ernst JA,
Scearce-Levie K, Couch JA, Dennis MS, Watts RJ. (2014) Therapeutic bispecific
antibodies cross the blood-brain barrier in nonhuman primates. Sci Transl Med
6(261):261ra154.
9. Olsen O, Kallop DY, McLaughlin T, Huntwork-Rodriguez S, Wu Z, Duggan CD,
Simon DJ, Lu Y, Easley-Neal C, Takeda K, Hass PE, Jaworski A, O'Leary DD,
Weimer RM, Tessier-Lavigne M. (2014) Genetic analysis reveals that amyloid
precursor protein and death receptor 6 function in the same pathway to control
axonal pruning independent of β-secretase. J Neurosci 34(19):6438-47.
10. Bien-Ly N, Yu YJ, Bumbaca D, Elstrott J, Boswell CA, Zhang Y, Luk W, Lu Y, Dennis
MS, Weimer RM, Chung I, Watts RJ. (2014) Transferrin receptor (TfR) trafficking
determines brain uptake of TfR antibody affinity variants. J Exp Med 211(2):233-44.

2. 11. Sun Y, Caplazi P, Zhang J, Mazloom A, Kummerfeld S, Quinones G, Senger K,
Lesch J, Peng I, Sebrell A, Luk W, Lu Y, Lin Z, Barck K, Young J, Del Rio M, Lehar
S, Asghari V, Lin W, Mariathasan S, DeVoss J, Misaghi S, Balazs M, Sai T, Haley B,
Hass PE, Xu M, Ouyang W, Martin F, Lee WP, Zarrin AA. (2014) PILRα negatively
regulates mouse inflammatory arthritis. J Immunol 193(2):860-70.
12. Couch JA, Yu YJ, Zhang Y, Tarrant JM, Fuji RN, Meilandt WJ, Solanoy H, Tong RK,
Hoyte K, Luk W, Lu Y, Gadkar K, Prabhu S, Ordonia BA, Nguyen Q, Lin Y, Lin Z,
Balazs M, Scearce-Levie K, Ernst JA, Dennis MS, Watts RJ. (2013) Addressing
safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci
Transl Med 5(183):183ra57, 1-12.
13. Jonsson T, Atwal JK, Steinberg S, Snaedal J, Jonsson PV, Bjornsson S, Stefansson
H, Sulem P, Gudbjartsson D, Maloney J, Hoyte K, Gustafson A, Yichin Liu, Lu Y,
Bhangale T, Graham RR, Huttenlocher J, Bjornsdottir G, Andreassen OA, Jonsson
EG, Palotie A, Behrens, TW, Magnusson OT, Kong A, Thorsteinsdottir U, Watts RJ,
Stefansson K. (2012) A mutation in APP protects against Alzheimer’s disease and
age-related cognitive decline. Nature 488(7409):96-9.
14. Xin Y, Bai S, Damico-Beyer LA, Jin D, Liang WC, Wu Y, Theil FP, Joshi A, Lu Y,
Lowe J, Maia M, Brachmann RK, Xiang H. (2012) Anti-Neuropilin-1 (MNRP1685A):
Unexpected pharmacokinetic differences across species, from preclinical models to
humans. Pharm Res 29(9):2512-21.
15. Bumbaca D, Tong RK, Koch AW, Xiang H, DeForge LE, Shen BQ, Lu Y*. (2012) A
case study on Sema3E-Fc aggregation and assay-dependent differences in
quantitation. Bioanalysis 4(6):703-11.
16. Deng R, Meng YG, Hoyte K, Lutman J, Lu Y, Iyer S, DeForge LE, Theil FP, Fielder
PJ, Prabhu S. (2012) Subcutaneous bioavailability of therapeutic antibodies as a
function of FcRn binding affinity in mice. mAbs 4(1):101-09.
17. Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, Lu Y, Atwal J, Elliot JM, Prabhu S,
Watts RJ, Dennis MS. (2011) Boosting a brain uptake of a therapeutic antibody by
reducing the affinity for a transcytosis target. Sci Transl Med 3(84):84ra44.
18. Atwal J, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y, Heise C, Hoyte K, Luk
W, Lu Y, Peng J, Wu P, Rouge L, Zhang Y, Lazarus RA, Scearce-Levie K, Wang W,
Wu Y, Tessier-Lavigne M, Watts RJ. (2011) A therapeutic antibody targeting BACE1
inhibits amyloid-beta production in vivo. Sci Transl Med 3(84):84ra43.
19. Lu Y, Vernes JM, Chiang N, Ou Q, Ding J, Adams C, Hong K, Truong BT, Ng D,
Shen A, Nakamura G, Gong Q, Presta LG, Beresini M, Kelley B, Lowman H, Wong
WL, Meng YG. (2011) Identification of IgG1 variants with increased affinity to FcRIIIa
and unaltered affinity to FcRI and FcRn: comparison of soluble receptor-based and
cell-based binding assays. J Immunol Methods 365(1-2):132-41.
20. Wilson NS, Yang B, Yang A, Loeser S, Marsters S, Lawrence D, Pitti R, Totpal K,
Yee S, Ross S, Vernes JM, Lu Y, Offringa R, Adams C, Kelley B, Hymowitz S,
Daniel D, Meng G, Ashkenazi A. (2011) An Fcg receptor-dependent mechanism

3. drives antibody-mediated target-receptor signaling in cancer cells. Cancer cell
19(1):101-13.
21. Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, Leong SR, Lee WP, Zhang J,
Sharma N, Lu Y, Iyer S, Shields RL, Chiang N, Bauer MC, Wadley D, Roose-Girma
M, Vandlen R, Yansura DG, Wu Y, Wu LC. (2010) Development of a two-part
strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor
signaling. J Biol Chem 285(27):20850-9.
22. Junttila TT, Parsons K, Olsson C, Lu Y, Xin Y, Theriault J, Crocker L, Pabonan O,
Baginski T, Meng G, totpal K, Kelley RF, Sliwkowski MX. (2010) Superior in vivo
efficacy of afucosylated trastuzumab in the treatment of HER2 amplified breast
cancer. Cancer Res 70(11):4481-9.
23. Lu Y*, Xiang H, Liu, P, Tong RT, Watts, RJ, Koch AW, Sandoval WN, Damico LA,
Wong WL, Meng YG. (2009) Identification of circulating neuropilin-1 and dose-
dependent elevation following anti-neuropilin-1 antibody administration. mAbs
1(4):364-9.
24. Junutula JR, Raab H, Clark S, Bhakta S, Leipold DD, Weir S, Chen Y, Simpson M,
Tsai SP, Dennis MS, Lu Y, Meng YG, Ng C, Yang J, Lee CC, Duenas E, Gorrell J,
Katta V, Kim A, McDorman K, Flagella K, Ross S, Spencer S, Wong WL, Lowman
HB, Vandlen R, Sliwkowski MX, Scheller RH, Polakis P, Mallet W. (2008) Site-
specific conjugation of cytotoxic drugs to antibodies substantially improves the
therapeutic window. Nat Biotechnol 26(8):884-5.
25. Lu Y, Young J, Meng YG. (2007) Electrochemiluminescence to detect surface
proteins on live cells. Curr Opin Pharmacol 7(5):541-6.
26. Shen A, Ng D, Joly J, Snedecor B, Lu Y, Meng YG, Nakamura G, Krummen L.
(2007) Metabolic engineering to control glycosylation. Cell Culture and Upstream
Processing. Book Chapter. Taylor and Francis group, England, pp. 132-148.
27. Lu Y, Wong WL, Meng YG. (2006) A high throughput electrochemiluminescent cell-
binding assay for therapeutic anti-CD20 antibody selection. J Immunol Methods
314(1-2):74-9.
28. Gong Q, Ou Q, Ye S, Lee WP, Cornelius J, Diehl L, Lin WY, Hu Z, Lu Y, Chen Y,
Wu Y, Meng YG, Gribling P, Lin Z, Nguyen K, Tran T, Zhang Y, Rosen H, Martin F,
Chan AC. (2005) Importance of cellular microenvironment and circulatory dynamics
in B Cell immunotherapy. J Immunol 174(2):817-26.
29. Hong K, Presta LG, Lu Y, Penn A, Adams C, Chuntharapai A, Yang J, Wong WL,
Meng YG. (2004) Simple quantitative live cell and anti-idiotypic antibody based
ELISA for humanized antibody directed to cell surface protein CD20. J Immunol
Methods 294(1-2):189-97.